Clinical Scorecard: Evaluating Radiologists' Ability to Differentiate Post-COVID-19 Lung Residuals from Interstitial Lung Disease Findings
At a Glance
Category
Detail
Condition
Post-COVID-19 residual lung abnormalities and interstitial lung abnormalities (ILA)
Key Mechanisms
Persistent lung CT findings post moderate to severe COVID-19 infection; ILA may progress to pulmonary fibrosis with fibrotic or non-fibrotic forms
Target Population
Patients with history of moderate to severe COVID-19 or those with interstitial lung abnormalities on chest CT
Care Setting
Radiology and pulmonary imaging settings, particularly in post-COVID-19 follow-up and ILD evaluation
Key Highlights
Post-COVID-19 residual lung abnormalities can resemble ILA on CT, complicating differentiation.
Radiologists’ ability to distinguish post-COVID-19 residuals from ILA based solely on CT without clinical history is underexplored.
Study involved multi-reader evaluation of 60 cases (20 post-COVID-19 residuals, 20 fibrotic ILA, 20 non-fibrotic ILA) using a standardized 5-point scale.
Guideline-Based Recommendations
Diagnosis
Use chest CT imaging to identify post-COVID-19 residual abnormalities and ILA patterns.
Apply a 5-point scale to assess likelihood of post-COVID-19 residuals versus ILA when clinical history is unavailable.
Consider ILA subtypes (fibrotic vs non-fibrotic) for further classification.
Management
Recognize that post-COVID-19 residual abnormalities may remain stable over time, similar to pulmonary fibrosis post-ARDS.
Monitor patients with ILA for potential progression to pulmonary fibrosis.
Monitoring & Follow-up
Long-term follow-up imaging may be necessary to assess stability or progression of lung abnormalities.
Collect clinical history of prior SARS-CoV-2 infection when possible to aid interpretation.
Risks
Misclassification of post-COVID-19 residuals as ILA or vice versa may impact prognosis and management.
Potential for overlooking progressive ILD if post-COVID-19 residuals are assumed stable without adequate monitoring.
Patient & Prescribing Data
Patients with prior moderate to severe COVID-19 infection and those with interstitial lung abnormalities detected on CT
No direct treatment data provided; emphasis on diagnostic differentiation to guide prognosis and management strategies.
Clinical Best Practices
Incorporate clinical history of SARS-CoV-2 infection during CT interpretation when feasible.
Use standardized imaging evaluation protocols and scoring systems to improve diagnostic consistency.
Engage experienced thoracic radiologists and multidisciplinary teams for challenging cases.
Recognize imaging patterns typical of post-COVID-19 residuals (e.g., ground-glass opacities with peribronchovascular distribution) versus ILA (subpleural, basal predominance).
by Jong Eun Lee, Hyo-Jae Lee, Gyeryeong Park, Kum Ju Chae, Kwang Nam Jin, Eva Castañer, Benoit Ghaye, Jane P. Ko, Helmut Prosch, Scott Simpson, Anna Rita Larici, Jeffrey P. Kanne, Thomas Frauenfelder, Yeon Joo Jeong, Soon Ho Yoon
